Mirum Pharmaceuticals Inc
MIRMHealthcare|Biotechnology|USA
$122.13
-5.67 (-4.44%)
Clinical Trials (40)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07290257 Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) | Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | P4 | Recruiting | 230 | Open-label | Livmarli Oral Product |
| NCT07454837 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | Chronic Hepatitis D | P2P3 | Recruiting | 120 | RCT, Open-label | Brelovitug (BJT-778), Bulevirtide |
| NCT06553768 Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | P3 | Active | 90 | RCT, Double-blind | Maralixibat |
| NCT06907290 A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Chronic Hepatitis D Infection | P2P3 | Active | 150 | RCT, Open-label | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg |
| NCT07200908 A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Chronic Hepatitis D Infection | P3 | Recruiting | 172 | RCT, Open-label | Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg |
| NCT07298330 A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Chronic Hepatitis D Infection | P3 | Active | 80 | RCT, Open-label | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg |
| NCT04663308 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | P2 | Active | 182 | RCT, Double-blind | Volixibat, Placebo |
| NCT05050136 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Primary Biliary Cholangitis, PBC | P2 | Recruiting | 260 | RCT, Double-blind | Volixibat, Placebo |
| NCT07209462 Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | Fragile X Syndrome | P2 | Recruiting | 60 | RCT, Double-blind | Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label |
| NCT03115086 The REPLACE Registry for Cholbam® (Cholic Acid) | Bile Acid Synthesis Disorders | Active | 55 | — | Cholbam | |
| NCT07411716 Pediatric Evaluation and Registry for Liver Cholestasis in Canada | PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS) | Recruiting | 220 | — | — | |
| NCT06193928 Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | Recruiting | 70 | — | Livmarli, Livmarli | |
| NCT04185363 An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | P3 | Completed | 84 | Open-label | Maralixibat |
| NCT00007020 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid | Infantile Refsum's Disease, Zellweger Syndrome | P3 | Completed | 85 | Open-label | Cholic Acids |
| NCT04270682 Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) | CTX | P3 | Completed | 19 | RCT, Double-blind | Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID |
| NCT01438411 Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis | Bile Acid Synthesis Defect | P3 | Completed | 53 | Open-label | Cholic Acid |
| NCT03353454 A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | P3 | Withdrawn | — | RCT, Double-blind | Maralixibat, Placebo |
| NCT03905330 A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | P3 | Completed | 93 | RCT, Double-blind | Maralixibat |
| NCT01115582 Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis | Inborn Errors of Bile Acid Synthesis | P3 | Completed | 16 | Open-label | Cholic acid |
| NCT04718961 A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) | Intrahepatic Cholestasis of Pregnancy | P2 | Terminated | 4 | RCT, Double-blind | Volixibat, Placebo |
| NCT02061540 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis (PSC) | P2 | Completed | 27 | Open-label | LUM001 |
| NCT07389031 Maralixibat for Intrahepatic Cholestasis of Pregnancy | Intrahepatic Cholestasis of Pregnancy | P2 | Not Yet Recruiting | 28 | Open-label | Maralixibat |
| NCT02321306 An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis | Primary Biliary Cirrhosis | P2 | Withdrawn | — | Open-label | LUM001 |
| NCT02117713 An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome | Alagille Syndrome | P2 | Completed | 34 | Double-blind | LUM001 (Maralixibat) |
| NCT01903460 Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome | Alagille Syndrome | P2 | Completed | 20 | RCT, Double-blind | LUM001, Placebo |
| NCT02047318 An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) | Alagille Syndrome | P2 | Completed | 19 | Open-label | LUM001 (Maralixibat) |
| NCT04524390 Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Biliary Atresia | P2 | Completed | 75 | RCT, Double-blind | Maralixibat |
| NCT04168385 MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study | Cholestatic Liver Disease | P2 | Completed | 52 | Open-label | Maralixibat |
| NCT04729751 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). | Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome | P2 | Completed | 27 | Open-label | Maralixibat |
| NCT02057692 Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome | Alagille Syndrome | P2 | Completed | 37 | RCT, Double-blind | LUM001, Placebo |
| NCT02787304 Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis | P2 | Terminated | 197 | RCT, Double-blind | SHP626, Placebo |
| NCT01904058 Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis | PBC, Primary Biliary Cirrhosis | P2 | Completed | 66 | RCT, Double-blind | LUM001, Placebo, Ursodeoxycholic Acid |
| NCT02160782 Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) | Alagille Syndrome | P2 | Completed | 31 | RCT, Double-blind | LUM001 (Maralixibat), Placebo |
| NCT02057718 Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis | Progressive Familial Intrahepatic Cholestasis (PFIC) | P2 | Completed | 33 | Open-label | LUM001 (Maralixibat) |
| NCT02571192 A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose | Non-Alcoholic Steatohepatitis | P1 | Completed | 8 | Open-label | SHP626 |
| NCT02475317 Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion | Healthy Volunteers | P1 | Completed | 84 | RCT, Double-blind | Placebo, Maralixibat, Volixibat |
| NCT02287779 Safety and Tolerability Study of SHP626 in Overweight and Obese Adults | Non-Alcoholic Steatohepatitis | P1 | Completed | 84 | RCT, Double-blind | SHP626, Placebo |
| NCT04530994 A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS) | Alagille Syndrome | APPROVED_FOR_MARKETING | — | — | maralixibat | |
| NCT05368038 ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2 | By Invite | 100,000 | — | — | |
| NCT02131623 Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease | Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | Completed | 23 | — | — |